There are reports of up-regulation of RBP4 in serum in the course of AMD, and drugs being developed to limit its expression, leading to a lower RBP4-mediated lipofuscin bisretinoid distribution into the retina, where they are involved in lipofuscin aggregation in RPE cells [20]. Here, RBP4 is linked to age-related macular degeneration.